Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
IDT and Aldevron launched PE Ultra prime-editor mRNA, chemically modified pegRNAs, and six ABE8e-based editor mRNAs with a parallel screening kit. The companies also described guide-design support and stocked quantities from 20 micrograms to 1 milligram. These are research-use products; the announcement does not establish clinical safety, efficacy, or approval.
Umoja announced four accepted ASH presentations, including clinical data from investigator-initiated studies of CD22-directed UB-VV400 in B-cell malignancies and UB-VV410 in lupus. Separate trial-in-progress posters concern UB-VV400 and BCMA/GPRC5D-directed UB-VV500. The announcement schedules December presentations rather than providing numerical response or safety results from those studies.
Tessera announced three preclinical presentations for the December 2026 ASH meeting. Topics include targeted LNP delivery for functional CAR-T generation in nonhuman primates and in vivo hematopoietic stem-cell editing for sickle cell disease. This is a company announcement of upcoming presentations, not a peer-reviewed publication or evidence of clinical benefit.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.
BioPharm International reported Shilpa CDMO's plan to invest $50 million in peptide manufacturing at Raichur, India. The phased expansion would add 10 kiloliters of solid-phase synthesis reactor capacity, beginning with a commercial line planned for December 2026. Commercial supply is expected to ramp during 2027; these are planned capabilities rather than demonstrated utilization.
In a company-issued release carried by BioSpace, Strand announced SITC presentations on intratumoral STX-001 and systemic STX-003, both self-replicating mRNA approaches expressing IL-12. The presentations cover updated STX-001 clinical findings and ASCENT-1 trial design for STX-003. The release does not provide numerical response rates or establish efficacy for systemic administration.
Alnylam announced AHA and ISA presentations covering vutrisiran in transthyretin amyloidosis, including five-year HELIOS-B follow-up with two years of open-label extension data. Planned analyses also examine exercise capacity, cardiopulmonary measures, and real-world treatment patterns. The announcement previews forthcoming presentations; open-label and post hoc analyses require interpretation distinct from randomized comparisons.
Precision BioSciences updated its ARCUS in vivo editing portfolio in its third-quarter report. The company described ongoing ELIMINATE-B evaluation of PBGENE-HBV and the Phase 1/2 FUNCTION-DMD study of PBGENE-DMD, which uses AAV delivery. Planned data releases and management expectations should be distinguished from completed clinical outcomes.
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.